Immunohistochemical expression of cdk 2 and Ki-67 in human endometrial carcinoma.

Akaboshi, Makoto; Watanabe, Jun; Fujisawa, Takeshi; Hattori, Manabu; Ohno, Eiji; Kuramoto, Hiroyuki

doi:10.5795/jjscc.40.121

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cells with >5% positive staining were classified as positive for p14 ARF . The results of p14 ARF expression were compared with those of Ki-67 (19), cyclin A (20), cyclin D1 (21), cyclin E (22), cdk2 (19), p27 (23), and p53 (24) expression.…”

Section: Evaluation Of Immunohistochemistrymentioning

confidence: 99%

Expression of Tumor Suppressor Gene Product p14ARF in Endometrioid Adenocarcinoma of the Uterine Corpus

Watanabe

Nishizaki²,

Jobo³

et al. 2004

International Journal of Gynecological Pathology

Self Cite

View full text Add to dashboard Cite

p14 activates p53 by inhibiting MDM2 expression and arrests the cell cycle in G1 and G2/M. Abnormal p14 expression has been reported in various human cancers. This study investigated p14 expression in endometrioid adenocarcinoma of the uterine corpus in an attempt to clarify its correlation with other cell cycle-regulators and clinicopathologic parameters. The specimen studied consisted of 124 endometrioid adenocarcinomas, 20 normal endometria, and 20 endometrial hyperplasias. Immunohistochemical staining of formalin-fixed and paraffin-embedded tissues was performed using a Catalyzed Signal Amplification System. Cells with >5% positive staining were classified as positive for p14. A staining score of 1 was adopted when the percentage of positive nuclei was <5%, a score of 2 when it was 5 to 50%, and a score of 3 when it was >50%. In normal endometrium, the frequency of positive staining in the proliferative phase and secretory phase was 50% (4/8) and 58.3% (7/12), with staining scores of 1.8+/-0.9 and 1.6+/-0.5, respectively. The frequency of staining in simple hyperplasia (SH), complex hyperplasia (CH), and complex atypical hyperplasia (CAH) was 88.9% (8/9), 25% (1/4), and 42.9% (3/7), respectively; the staining scores were 1.9+/-0.3, 1.3+/-0.5, and 1.4+/-0.5, respectively. Among endometrioid adenocarcinomas, the frequency of staining of well-differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) adenocarcinomas was 69% (49/71), 64% (16/25), and 42.9% (12/28) respectively, with staining scores of 2.1+/-0.8, 2+/-0.9, and 1.8+/-1, respectively. Thus expression levels of p14 were higher in G1 tumors than in normal endometria or endometrial hyperplasias, and the frequency of its staining in endometrioid carcinomas was inversely correlated with histologic grade. The staining score for endometrioid adenocarcinomas also was inversely correlated with the labeling index (LI) of Ki-67, but not with that of cyclin A, cyclin D1, cyclin E, cdk2, p27, p53, or other clinicopathologic parameters. In conclusion, p14 expression correlated with histologic grade and Ki-67, but not other prognostic factors in endometrioid adenocarcinoma. Long-term follow-up studies are needed to analyze the significance of p14 expression in these tumors.

show abstract

Section: Evaluation Of Immunohistochemistrymentioning

confidence: 99%

Expression of Tumor Suppressor Gene Product p14ARF in Endometrioid Adenocarcinoma of the Uterine Corpus

Watanabe

Nishizaki²,

Jobo³

et al. 2004

International Journal of Gynecological Pathology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results of PR-A and -B expressions were compared with those of Ki-67, cyclin E, cyclin A, cyclin D1, cdk2, p27 and p53, which had been analyzed at our laboratory [6][7][8][9][10][11]. In brief, for immunostaining of Ki-67, cyclin E, cyclin A, cyclin D1, cdk2, p27 and p53, rabbit polyclonal anti-Ki-67 antibody (DAKO, 1:50 dilution), mouse monoclonal anti-cyclin E antibody (13A3, Novocastra, 1:40 dilution), mouse monoclonal anti-cyclin A antibody (6E6, Novocastra, 1:100 dilution), mouse monoclonal anti-cyclin D1 antibody (DCS-6, Oncogene, 1:80 dilution), rabbit polyclonal anti-cdk2 antibody (M2, Santa Cruz Biotechnology, 1:2000 dilution), mouse monoclonal anti-p27 antibody (1B4, Novocastra, 1:200 dilution) and mouse monoclonal anti-p53 antibody (DO-7, Novocastra, 1:80 dilution) were used for a labeled streptavidin-biotin methods (LSAB kit, DAKO).…”

Section: Immunohistochemical Stainingmentioning

confidence: 99%

“…Traditional factors associated with its prognosis include tumor grade, depth of uterine myometrial invasion and stage [5]. We previously showed that cell cycle-regulatory proteins such as Ki-67, cyclin E, cyclin A, cyclin D1, cyclin-dependent kinase (cdk) 2, p27 and p53 were correlated with the malignant potential of endometrial adenocarcinoma [6][7][8][9][10][11]. In addition, the most extensively studied biologic markers in endometrial carcinoma are ER and PR.…”

Section: Introductionmentioning

confidence: 99%

Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma

Miyamoto¹,

Watanabe²,

Hata³

et al. 2004

The Journal of Steroid Biochemistry and Molecular Biology

Self Cite

View full text Add to dashboard Cite

“…Positive staining was evaluated by counting approximately 1,000 cells in high-power fields and was expressed as the labeling index (LI), which was regarded as the percentage of positive nuclei. The result of skp2 expression was compared with those of p27, Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p53 and PTEN, which had been analyzed in our laboratory Akaboshi et al 2001;Kyushima et al 2002;Nishimura et al 2004;Kato et al 2003;Fujisawa et al 2001;Kimura et al 2004). …”

Section: Immunohistochemistrymentioning

confidence: 99%

High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma

Kamata

Watanabe

Nishimura

et al. 2005

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

Immunohistochemical expression of cdk 2 and Ki-67 in human endometrial carcinoma.

Abstract: Immunohistochemical expression of cdk 2 and Ki-67 in human endometrial carcinoma Makoto AKABOSHI1), C.T., I.A

Cited by 7 publications

References 0 publications

Expression of Tumor Suppressor Gene Product p14ARF in Endometrioid Adenocarcinoma of the Uterine Corpus

Expression of Tumor Suppressor Gene Product p14ARF in Endometrioid Adenocarcinoma of the Uterine Corpus

Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma

High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma

Contact Info

Product

Resources

About